Merck Reports 12.9% Sales Growth in 2022 Annual Report
German major Merck (NYSE: MRK) released its 2022 annual report this week, showing a robust...
NYSE: MRK
Merck & Co. Posts 22% YOY Sales Growth; Keytruda and Gardasil Drive Revenues
Merck & Co. (NYSE: MRK) has released its Q4 and full-year 2022 financial report, showcasing...
Zhifei Renews Vaccine Supply Agreement with Merck Sharp & Dohme
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the renewal of a supply,...
MSD China to Take Legal Action Against Market Infringement of Molnupiravir
Merck Sharp & Dohme (MSD, NYSE: MRK)’s China unit has issued a WeChat notification vowing...
Kelun-Biotech’s SKB264 Approved for Phase II Study in EGFR-Mutant NSCLC
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the National Medical Products...
MSD Submits Initial Quotation for Molnupiravir in China Amid New COVID-19 Rules
Under new rules specifically for the launch of COVID-19 therapeutics in China, US-based Merck Sharp...
Merck’s Lagevrio Receives Emergency Conditional Approval from China’s NMPA
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced receiving emergency conditional approval...
Sichuan Kelun Completes RMB 1.5 Billion Financing Round for Kelun-Biotech
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced the completion of a financing...
Antengene and MSD Collaborate on Global Clinical Study for ATG-037
China-based Antengene Corporation Limited (HKG: 6996) has announced a global clinical collaboration with Merck, Sharp...
MSD and Kelun Biotech Ink Record-Breaking ADC Deal
Merck, Sharp & Dohme (MSD, NYSE: MRK) has set a new benchmark for the largest...
Merck Launches Noxafil in China for Antifungal Treatment
US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) has announced the official market launch...
Doer Bio and MSD Collaborate on Clinical Trial for Anti-Claudin18.2 Antibody DR30303
China-based Zhejiang Doer Biologics Co., Ltd has announced a clinical trial collaboration agreement with US...
Merck Partners with Tsinghua Shenzhen for Organoid 3D Printing System
Germany giant Merck (NYSE: MRK) struck a three-year partnership with Tsinghua Shenzhen International Graduate School,...
Merck’s Keytruda Receives 10th Indication Approval in China for TNBC
US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has...
Organon Partners with Alibaba Health to Enhance Chronic Disease Management
Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that...
Organon Sponsors Retail Pharmacy Health Center at CIIE
The 5th China International Import Expo (CIIE) saw Organon & Co. (NYSE: OGN), a firm...
Organon’s Q3 Results Show Women’s Health Segment Outperforms Amid Global Revenue Decline
US-based Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health...
Organon Signs MOU with China’s National Health Commission at CIIE
Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that...
Merck’s Q3 Sales Rise on Key Drug Performances, China Growth
US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) reported its Q3 2022 financial results,...
Merck’s Keytruda Gains 9th Indication Approval in China for Hepatocellular Carcinoma
US major Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab)...